Put Options

14 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q4 2021

Feb 14, 2022

BUY
$53.63 - $62.52 $10.8 Million - $12.6 Million
201,100 Added 1779.65%
212,400 $13.2 Million
Q3 2021

Nov 15, 2021

SELL
$59.17 - $69.31 $6.22 Million - $7.29 Million
-105,200 Reduced 90.3%
11,300 $669,000
Q2 2021

Aug 16, 2021

SELL
$61.91 - $67.42 $17.3 Million - $18.8 Million
-279,000 Reduced 70.54%
116,500 $7.79 Million
Q1 2021

May 17, 2021

BUY
$59.34 - $66.74 $22 Million - $24.7 Million
370,800 Added 1501.21%
395,500 $25 Million
Q4 2020

Feb 16, 2021

SELL
$57.74 - $65.43 $7.6 Million - $8.61 Million
-131,600 Reduced 84.2%
24,700 $1.53 Million
Q3 2020

Nov 16, 2020

BUY
$57.43 - $63.64 $8.74 Million - $9.69 Million
152,200 Added 3712.2%
156,300 $9.42 Million
Q2 2020

Aug 14, 2020

SELL
$54.82 - $64.09 $16.6 Million - $19.4 Million
-302,800 Reduced 98.66%
4,100 $241,000
Q1 2020

May 15, 2020

BUY
$46.4 - $67.43 $8.95 Million - $13 Million
192,900 Added 169.21%
306,900 $17.1 Million
Q4 2019

Feb 14, 2020

SELL
$49.21 - $64.19 $910,385 - $1.19 Million
-18,500 Reduced 13.96%
114,000 $7.32 Million
Q3 2019

Nov 14, 2019

BUY
$42.77 - $50.71 $1.35 Million - $1.6 Million
31,600 Added 31.32%
132,500 $6.72 Million
Q2 2019

Aug 14, 2019

BUY
$44.62 - $49.34 $2.06 Million - $2.27 Million
46,100 Added 84.12%
100,900 $4.58 Million
Q3 2018

Nov 14, 2018

SELL
$55.19 - $62.25 $3.73 Million - $4.21 Million
-67,600 Reduced 55.23%
54,800 $3.4 Million
Q2 2018

Aug 14, 2018

BUY
$50.53 - $62.98 $2.3 Million - $2.87 Million
45,500 Added 59.17%
122,400 $6.77 Million
Q1 2018

May 15, 2018

BUY
$59.92 - $68.98 $4.61 Million - $5.3 Million
76,900 New
76,900 $4.86 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $88.3B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.